Pancreatic cancer remains one of the most challenging of all cancers. Genetic risk factors are believed to play a major role, but other than genes coding for blood group, genetic risks for sporadic cases remain elusive. However, several germline mutations have been identified that lead to hereditary pancreatic cancer, familial pancreatic cancer, and increased risk for pancreatic cancer as part of a familial cancer syndrome. The most important genes with variants increasing risk for pancreatic cancer include BRCA1, BRCA2, PALB2, ATM, CDKN2A, APC, MLH1, MSH2, MSH6, PMS2, PRSS1, and STK11. Recognition of members of high-risk families is important for understanding pancreatic cancer biology, for recommending risk reduction strategies and, in some cases, initiating cancer surveillance programs. Because the best methods for surveillance have not been established, the recommendation to refer at-risk patients to centers with ongoing research programs in pancreatic cancer surveillance is supported.
P ancreatic cancer is a rapidly progressive and usually fatal disorder that has risen to be the fourth leading cause of cancer deaths in the United States. 1 Lifetime risk for developing pancreatic cancer is approximately 1 in 71 individuals, with the majority of cases diagnosed between ages 60 and 80 years. 2 More than a dozen types of pancreatic neoplasms have been classified by the World Health Organization, but ductal adenocarcinomas comprise nearly 90% of cases and are clearly the most lethal.
Inherited risk factors contribute to at least 5% to 10% of all pancreatic adenocarcinoma cases, 3 but the recognized contribution of genetic risk is likely to rise dramatically as complex risk combinations are recognized. Genetic variants in several genes have been identified as strong dominant risk factors, however, not all cases of inherited pancreatic cancer can be linked to a known gene. 4 Thus, families of pancreatic cancer patients and other individuals may be at increased risk of pancreatic cancer, but no tests are available to determine whether these risk factors are present. However, in other cases, risk factors have been identified, and organs at highest risk of developing malignancies are known.
We review clinical and genetic data on the inherited genetic syndromes associated with pancreatic cancer risk and current medical management options for pancreas surveillance in high-risk populations. Furthermore, we discussed allelic variants as they relate to specific patient populations.
HEREDITARY AND FAMILIAL PANCREATIC CANCERS
Germline mutations conferring risk of pancreatic cancer are suggested in kindred with multiple generations of pancreatic or related cancers, cancer diagnoses at younger than 50 years, individuals with synchronous and/or metachronous tumors, unusual or rare tumors including tumors more frequent in the opposite gender, and/or families with ethnicity known to have an increased mutation carrier frequency. 5 Furthermore, the presence of pancreatic cancer in a family increases pancreatic cancer risk for relatives regardless of the known gene mutation. 3 Thus, a good family history is critical to the management of pancreatic cancer risk.
Definition of Hereditary and Familial Pancreatic Cancer
Hereditary pancreatic cancer is defined as a genetic syndrome with an identifiable gene mutation associated with an increased risk for pancreatic cancer. Familial pancreatic cancer (FPC) is defined as a family with at least 1 pair of first-degree relatives (parent-child or sibling pair) with pancreatic cancer without an identifiable syndrome in the family. 3 Relatives meeting the FPC criteria have an increased risk over the general population for developing pancreatic cancer (Table 1) . These individuals can be further stratified dependent on relationships to the affected relatives. An individual with 3 or more firstdegree relatives with pancreatic cancer in a family meeting the FPC definition carries up to a relative risk (RR) of 17 for pancreatic cancer. 6 Furthermore, smoking history exacerbates pancreatic cancer risk in the FPC setting as well as reduces age of onset by up to a decade. 7
Surveillance for Early Pancreatic Cancer in FPC
Currently the best treatment option for pancreatic cancer is surgical excision. Pancreatic cancer metastasizes early and progresses rapidly. Therefore, the only cases that have a reasonable chance for a cure or prolonged survival are ones that are detected as high-risk lesions or very early (G2 cm) isolated tumors. At-risk relatives who meet the FPC criteria warrant pancreatic surveillance. 3 The type, frequency, and age to begin surveillance are not yet well defined. Some centers utilize endoscopic ultrasound and/or magnetic resonance imaging surveillance programs, both of which detect pancreatic lesions better than does computed tomography. 8 generations of a family often with diagnoses before age 50 years. 9 The majority of cases of HBOC are due to mutations in the BRCA1 or BRCA2 genes ( Table 2 ).
The BRCA1-BRCA2 HBOC is the most common form of inherited breast and ovarian cancer, accounting for 90% to 95% of inherited breast and ovarian cancers, respectively. 10Y12 The incidence of HBOC in the general population is approximately 1 in 500 individuals. Carrier frequency is increased among patients with Ashkenazi (Eastern European) Jewish ethnicity, with 1 in 40 individuals at risk. Specifically, there are 3 founder mutations in this population: 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2. 13
BRCA1
The BRCA1 gene, located at 17q21.31 (OMIM: 113705), codes for a protein complex regulating DNA repair, cell cycle checkpoint controls, and maintaining genomic stability. Mutations in BRCA1 are primarily associated with early-onset breast and ovarian cancer risks, although other cancer risks do occur at higher rates than expected in the general population including pancreatic cancer. Brose and colleagues 14 reported a relative risk of 2.8 compared with the general population risk of 1.3% for pancreatic cancer in BRCA1 mutation carriers. In chronic pancreatitis, which is a risk factor for pancreatic cancer, and in pancreatic cancer tumors, there is a down-regulation of BRCA1 mRNA and protein. 15 This suggests that BRCA1 may play a role in protecting the pancreas from cancer development. However, Moran and colleagues 16 reported a series of 268 
BRCA2
BRCA2, located on 13q13.1 (OMIM #600185), was identified in 1995 as an associated candidate gene in familial breast cancer. 18 The BRCA2 protein product functions as a tumor suppressor by way of interactions with rad51-dependent DNA repair. 19 BRCA2 mutations increase breast and ovarian cancer risk and other cancers including male breast, prostate, melanoma, and pancreatic cancer. 16 BRCA2 mutations are the most common form of inherited pancreatic cancer risk. 20 Kindred with at least 3 or more cases of pancreatic cancer have a 15% to 17% chance for carrying a BRCA2 mutation. 21 Analysis of 222 BRCA2 families identified a statistically significant increased risk for pancreatic cancer (RR, 4.1; 95% confidence interval, 1.9Y7.8). 16 The Breast Cancer Linkage Consortium indicated that BRCA2 mutation carriers have an RR of 3.5 compared with nonYmutation carriers (5%Y7% lifetime risk) for developing pancreatic cancer. 22 In a genomic sequencing study of unselected, apparently sporadic pancreatic cancers, 3 (7.3%) of 41 were found to harbor germline BRCA2 mutations, none of which had family history of pancreatic cancer, indicating that multiple underlying genetic factors increase the risk for pancreatic cancer.
An important reason for identifying BRCA2 mutations is the potential of novel treatments. Specifically, personalizing treatment of BRCA2-related cancers may benefit from the use of PARP (poly[ADP ribose] polymerase) enzyme inhibitors. PARP enzymes play a role in the DNA repair pathway. In BRCA+, tumors can be highly sensitive to PARP inhibitors by way of inducing DNA breaks, leading to irreversible damage and tumor cell death, while sparing normal, healthy cells. 23 Clinical benefit has been reported and is currently under investigation. 24 Animal studies confirm a major role for BRCA2 in a mouse model of FPC. Feldmann and colleagues 25 developed a double conditional BRCA2 knockout mouse with and without the Trp53 (R172H) deregulating variant. Mice with the BRCA2(j/j) background resulted in widespread DNA damage throughout the exocrine pancreatic cells, with development of pancreatic intraepithelial neoplasia (PanIN lesions) in most mice and invasive pancreatic ductal adenocarcinoma in about 15% of mice. Combining BRCA2(j/j) and the Trp53 (R172H) variants accelerated carcinogenesis. The authors conclude that loss of BRCA2 function predisposes the exocrine pancreas to profound DNA damage, and the frequency of invasive neoplasia is accentuated by the concomitant deregulation of p53. 25 However, in humans, Brose and colleagues 14 did not see the common loss of BRCA2 mRNA expression and protein in sporadic tumors as they had seen with BRCA1. Taken together, these data suggest that patients with BRCA2 mutations are at increased risk for pancreatic cancer but that this pathway is not essential or common in sporadic pancreatic cancers.
The high risk of pancreatic cancer in BRCA2 warrants consideration for possible surveillance. For reasons that are not yet understood, some large BRCA2 kindred have multiple cases of pancreatic cancer, whereas others have none. Therefore, pancreatic surveillance is recommended only for BRCA2 mutation carriers with a family history of pancreatic cancer. Surveillance may include endoscopic ultrasound or magnetic resonance imaging evaluations. Currently, there are no formal guidelines for pancreatic cancer surveillance or medical management in the HBOC patient population. However, for other cancers associated with HBOC, the National Comprehensive Cancer Network set forth aggressive, early-onset management guidelines for breast and ovarian cancers.
FAMILIAL PANCREATIC CANCERS ASSOCIATED
WITH THE FANCONI ANEMIA DNA REPAIR PATHWAY
PALB2
The partner and localizer of BRCA2 (PALB2) gene (OMIM #610355) was originally identified as a breast cancer susceptibility gene associated within the Fanconi anemia DNA repair pathway (FANCN). Rahman and colleagues 26 identified monoallelic truncating mutations in 10 of 923 patients with familial breast cancer indicating a 2.3-fold high risk for breast cancer. In 2009, the first article was published reporting PALB2 as a FPC susceptibility gene. 27 Jones and colleagues 27 estimated that approximately 3% to 4% of FPC families may harbor a mutation in PALB2. Analysis of PALB2 in BRCA-negative families identified a 4-fold increased risk for male breast cancer and a 6-fold increased risk for pancreatic cancer in relatives of the mutation carrier. 28 The importance of PALB2 is yet to be established in larger populations. Recommendations for surveillance have not been established, but individuals from FPC kindred should be counseled according to the FPC risk, with greater risk assumed if PALB2 tracks with cancer in the family.
ATAXIA TELANGIECTASIA

ATM
Ataxia telangiectasia (AT) is a rare autosomal recessive condition characterized by early-onset progressive cerebellar ataxia, telangiectasia of the skin, ionizing radiation sensitivity, and immunodeficiency. Ataxia telangiectasia presents during the first decade of life in biallelic mutation carriers, and these individuals carry a 38% risk for cancer. The gene affected is the ATM gene. Monoallelic mutation carriers harbor cancer risks including breast and pancreas. Female mutation carriers are reported to have an increased risk for breast cancer equal to that of having 1 first-degree relative with breast cancer. 29 The possible importance of ATM in pancreatic cancer was highlighted in BxPC-3 cells (containing wild-type K-ras), which were treated with curcumin. 30 Curcumin resulted in phosphorylation of ATM at Ser-1981, G2/M cell cycle arrest, and apoptosis of the tumor cells. 30 This beneficial effect of curcumin was eliminated with siRNA silencing of ATM.
In a recent analysis of 166 unrelated FPC patients, 2.4% were identified as ATM mutation arriers. 31 Furthermore, 4.6% of FPC patients carried an ATM mutation if there were more than 3 cases of pancreatic cancer in their relatives. 31 Analyses of gene function are necessary to elucidate pancreatic cancer relationship to AT.
Genetic counseling and specific medical management are warranted for families with ATM mutations, and guidance is available. 32 Pancreatic cancer surveillance is not clearly defined in this population, although patients meeting the FPC definition may consider pancreatic surveillance programs.
FAMILIAL ATYPICAL MULTIPLE MOLE
MELANOMA SYNDROME
CDKN2A
The familial atypical multiple mole melanoma syndrome is characterized by an increased predisposition toward dysplastic nevus and early-onset melanoma in an autosomal dominant inheritance pattern. CDKN2A, a cell cycle regulator gene coding for the p16 protein product, has functional effects in melanoma and pancreatic cancer cell lines, thus implicating it as a potential risk factor for inherited pancreatic cancer risk. 33 Vasen and colleagues 34 determined that a germline founder mutation in a Dutch cohort was associated with up to a 17% lifetime risk for pancreatic cancer in this familial atypical multiple mole melanoma syndrome family. In other FPC kindred, mutations throughout CDKN2A have been observed without melanomas. 35 In a series of 120 American non-Hispanic pancreatic cancer cases with a family history of pancreatic cancer, 3.3% carried a CDKN2A mutation. Furthermore, the penetrance for developing pancreatic cancer was estimated at 58% by age 80 years for mutation carriers.
Medical management is rigorously suggested to begin in childhood because of the rapid and early-onset development of atypical nevi. Recommendations include semiannual dermatology evaluations including baseline photography beginning in childhood as well as pancreatic cancer surveillance consideration. Lifestyle modification includes applying SPF lotions and limiting sun exposure. Pancreatic cancer risk appears to be especially high in smokers, 35 and minimizing such exposure is recommended.
FAMILIAL ADENOMATOUS POLYPOSIS
APC
Familial adenomatous polyposis (FAP) syndrome is classically known for the multitude of early-onset gastrointestinal adenomas. In this autosomal dominant condition, symptoms present on average at age 16 years. 36 Inherited mutations in the tumor suppressor gene, APC, account for the majority of cases. Although the primary cancer risk in FAP is colon cancer, extracolonic risks including duodenal, thyroid, hepatic, and pancreatic cancers exist. Small-bowel cancers occur in 50% to 90% of patients with FAP and are usually periampullary. 37 Hepatoblastoma is observed in early childhood and poses a risk of 1.6%. Thyroid cancers are observed in approximately 2% of patients with FAP. Pancreatic cancer is considered a low-risk cancer, although it is observed in FAP families with higher incidence than in the general populations. Surveillance for FAPrelated cancer includes an intensive medical regimen consisting of yearly colonoscopies starting in the second decade until the presence of polyps is too numerous to remove via polypectomy. Total colectomy is recommended for the treatment of polyps and prevention of colon cancer. Esophagogastroduodenoscopy is recommended starting by age 25 years every 1 to 3 years or before colectomy. Extracolonic surveillance includes hepatoblastoma evaluations for pediatric patients and complete physical examination annually. 38 Pancreas surveillance may be considered for such families where pancreatic cancer is present.
LYNCH SYNDROME (HEREDITARY NONPOLYPOSIS COLORECTAL CANCER)
Lynch syndrome accounts for approximately 2% to 5% of all colorectal cancers diagnoses and is the most common cause of inherited colon cancer. Substantially increased cancer risks for colon and extracolonic tumors exist in patients with Lynch syndrome. The lifetime colorectal cancer risk ranges from 52% to 82% with a mean diagnosis age of 44 years. Other lifetime cancer risks include endometrial cancer (25%Y60%), ovarian cancer (4%Y12%), gastric (6%Y13%), and pancreatic cancer (1.3%Y4%). 39, 40 Pancreatic cancer was observed in 2 of 282 cancers diagnosed in a series of 121 families with known germline mutations. Whereas this report identified a low cumulative incidence, others have identified higher risks for Lynch syndromeY associated pancreatic cancer. Geary and colleagues 41 identified a 30-fold increased risk for pancreatic cancer before the age of 50 years and an almost 9 times as likely overall risk in a cohort of 147 families with Lynch syndrome.
Lynch syndrome tumors arise from germline mutations in mismatch repair genes such as MLH1, MSH2, MSH6, and PMS2. As such, the mismatch repair dysfunction results in loss of protein expression and microsatellite instability in tumors. Analysis of tumor tissue may establish or exclude a Lynch syndrome diagnosis. However, approximately 10% to 15% of sporadic colon tumors display this phenotype, leaving clinicians to utilize family history as a means for risk assessment in some cases. It is anticipated that, with the growing practice of universal testing of newly diagnosed colon cancers, many new cases of Lynch syndrome will be diagnosed.
HEREDITARY PANCREATITIS
PRSS1
Although rare, hereditary pancreatitis (HP) is among the only known inherited cancer predisposition syndrome for which pancreatic cancer is the sole cancer risk factor. Hereditary pancreatitis is an inherited form of chronic pancreatitis, in which a subset of families carries gain-of-function mutations in PRSS1. 42 Symptom onset begins in the first to second decade of life, although penetrance is estimated at 80%. 43 Recurrent acute pancreatitis attacks develop into chronic pancreatitis and pain leading to pancreas dysfunction, diabetes, and pancreatic cancer risk. Rebours et al 44 described that the pancreatic cancer risk ranges from 18% to 53% in a French cohort.
PRSS1 codes for cationic trypsinogen, a digestive enzyme. Premature activation of trypsin within the pancreas is believed to cause activation of the other digestive enzymes, resulting in pancreatic autodigestion and chronic inflammation. 45 The incidence of pancreatic cancer in these families increases after 20 to 40 years of chronic pancreatitis, with earlier onset and higher incidence in smokers and patients with diabetes. 46, 47 The importance of inflammation in initiating the epithelial to mesenchymal transition and pancreatic cancer, especially in the presence of KRAS G12D mutations, has recently been published. 48, 49 The challenge with surveillance of HP patients for pancreatic cancer is the gross distortion of the pancreatic architecture by chronic pancreatitis. One option for patients at high risk is total pancreatectomy, 50 with or without islet autotransplantation. 51 With recognition that risk is markedly reduced in nonsmokers and in patients with no diabetes and that some large HP families have never had a case of pancreatic cancer, caution is required in recommending this irreversible and potentially dangerous procedure.
PEUTZ-JEGHERS SYNDROME
STK11
Peutz-Jeghers syndrome (PJS) is caused by mutations in STK11 and presents with mucocutaneous hyperpigmentation and hamartomatous polyposis. Pancreatic cancer risk has been reported as high as a 132-fold risk in patients with PJS. 52 Although a rare syndrome, PJS currently confers the greatest defined inherited risk factor for pancreatic cancer.
GENETIC COUNSELING AND RISK ASSESSMENT
Patient identification for pancreatic cancer risk stratification because of inherited factors is complex ( Table 2 ). Pedigree analysis, molecular tumor studies, and germline mutation testing collectively offer patients the most accurate risk assessment. In addition to the medical complexities, a family history of pancreatic cancer can be emotionally trying for the high-risk healthy relative. In a series of high-risk family members, Maheu and colleagues 53 evaluated perception of cancer risk and identified that relatives who had increased worry before beginning pancreatic cancer surveillance may benefit from a comprehensive risk assessment and counseling program. Because no consensus guidelines exist for patients at high risk for inherited pancreatic cancer syndromes, clinical judgment and personalized counseling may be considered for this population. At the time of publication, patients meeting the FPC definition or those with known inherited cancer syndromes with a family history pancreatic cancer may consider a pancreatic cancer surveillance program. Thus, it is generally recommended that surveillance of these patients be performed only in centers experienced in caring for these high-risk patients, ideally enrolling them into research protocols.
